🇺🇸 FDA
Pipeline program

IFx-Hu2.0

SC 2020-01

Phase 1 mab completed

Quick answer

IFx-Hu2.0 for Cutaneous Squamous Cell Carcinoma is a Phase 1 program (mab) at TuHURA Biosciences, Inc./NV with 1 ClinicalTrials.gov record(s).

Program details

Company
TuHURA Biosciences, Inc./NV
Indication
Cutaneous Squamous Cell Carcinoma
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials